Monitor upcoming data readouts for NMRA-511 (Q4 2026) and NMRA-898 (H2 2026) as these are the next major catalysts. Cash runway into Q3 2027 suggests no near-term financing urgency, but the burn rate implies a potential capital raise in 2027 if no partnering or milestone payments materialize.
Price Chart
Executive Summary
Neumora Therapeutics reported Q2 2026 results with a net loss of $43.1M ($0.23 per share), in line with consensus estimates. The company also announced a leadership transition: co-founder Paul Berns becomes Executive Chair, President Joshua Pinto succeeds as CEO, and Doron Sagman joins as CMO. Cash stood at $116.8M, expected to fund operations into Q3 2027. Pipeline timelines remain on track with key data readouts expected in H2 2026.
Key Financial Metrics
Key Facts
- Net loss of $43.1M ($0.23 per share) for Q2 2026, in line with consensus of $0.23 loss per share
- Cash and cash equivalents of $116.8M as of June 30, 2026, down from $182.5M at Dec 31, 2025
- Leadership transition: Paul Berns becomes Executive Chair, Joshua Pinto appointed CEO and board member, Doron Sagman named CMO
- NMRA-215 (NLRP3 inhibitor for obesity) expects IND submission in Q4 2026 and Phase 1 start by end of 2026
- NMRA-511 (AD agitation) MAD expansion cohort data expected Q4 2026; Phase 2 start by end of 2026
- NMRA-898 (schizophrenia) Phase 1 data expected in H2 2026
- R&D expense decreased to $29.3M from $38.7M year-over-year; G&A decreased to $12.9M from $15.3M
Financial Impact
No material financial impact; net loss narrowed year-over-year but cash burn continues at ~$33M per quarter
Risk Factors
- Cash burn rate of ~$33M per quarter may require financing before Q3 2027
- Clinical trial risks for navacaprant (KOASTAL) and early-stage pipeline programs
- No revenue; full dependence on pipeline success and capital markets
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-350349 |
| Document: nmra-20260814.htm | 0001193125-26-350349 |
| Document: 0001193125-26-350349-index-headers.html | 0001193125-26-350349 |
| Document: 0001193125-26-350349-index.html | 0001193125-26-350349 |
| Document: 0001193125-26-350349.txt | 0001193125-26-350349 |
| 8-K Data (Synthetic) | 0001193125-26-350349 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 20, 2026 6w ago | 144 | $1.63 $0.6918 | ▲ +57.56% | ▲ +57.03% | $0.4999 (+69.33%) |
Aug 17, 2026 6w ago | 144 | $1.64 $0.7732 | ▲ +52.85% | ▲ +51.54% | $0.4999 (+69.52%) |
Aug 14, 2026 7w ago | 8-K | $1.60 $0.9994 | ▼ −37.54% | ▼ −35.55% | $0.4999 (−68.76%) |
Aug 14, 2026 7w ago | Press Release | $1.60 $0.9994 | ▼ −37.54% | ▼ −35.55% | $0.4999 (−68.76%) |
Jul 27, 2026 9w ago | 8-K | $1.66 $1.53 | ▼ −8.13% | ▼ −11.43% | $0.4999 (−69.89%) |
Jul 27, 2026 9w ago | Press Release | $1.66 $1.53 | ▼ −8.13% | ▼ −11.43% | $0.4999 (−69.89%) |
Jun 15, 2026 15w ago | 8-K | $0.9145 $1.60 | ▼ −74.96% | ▼ −75.71% | $0.4999 (+45.34%) |
Apr 17, 2026 24w ago | DEFA14A | $2.19 $1.77 | ▼ −19.18% | ▼ −23.38% | $0.4999 (−77.17%) |
Mar 30, 2026 26w ago | Press Release | $1.93 $2.25 | ▲ +16.58% | ▲ +3.98% | $0.4999 (−74.10%) |
Mar 16, 2026 28w ago | Press Release | $2.87 $2.03 | ▼ −29.27% | ▼ −33.05% | $0.4999 (−82.58%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access